These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 27471815

  • 1. Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study.
    Tanaka Y, Takeuchi T, Akashi N, Takita Y, Kovacs B, Kariyasu S.
    Mod Rheumatol; 2017 Mar; 27(2):284-291. PubMed ID: 27471815
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
    Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, Morgan-Cox M, Iikuni N, Silk M, Wallace DJ.
    Ann Rheum Dis; 2016 Feb; 75(2):323-31. PubMed ID: 26338095
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
    Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, Dickson C, Anderson PW, Lee C, Berclaz PY, Dörner T.
    Ann Rheum Dis; 2016 Feb; 75(2):332-40. PubMed ID: 26293163
    [Abstract] [Full Text] [Related]

  • 4. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group.
    Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population: Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O).
    Genovese MC, Silverman GJ, Emery P, Gupta RC, Gill A, Veenhuizen M, Xie L, Komocsar WJ, Berclaz PY, Lee C.
    J Clin Rheumatol; 2015 Aug; 21(5):231-8. PubMed ID: 26203826
    [Abstract] [Full Text] [Related]

  • 6. The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials.
    Rovin BH, Dooley MA, Radhakrishnan J, Ginzler EM, Forrester TD, Anderson PW.
    Lupus; 2016 Dec; 25(14):1597-1601. PubMed ID: 27220348
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
    van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S.
    Lancet; 2018 Oct 13; 392(10155):1330-1339. PubMed ID: 30249507
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.
    Wallace DJ, Strand V, Merrill JT, Popa S, Spindler AJ, Eimon A, Petri M, Smolen JS, Wajdula J, Christensen J, Li C, Diehl A, Vincent MS, Beebe J, Healey P, Sridharan S.
    Ann Rheum Dis; 2017 Mar 13; 76(3):534-542. PubMed ID: 27672124
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus.
    Witcher J, Fleischmann R, Chindalore VL, Hansen RJ, Hu L, Radtke D, Voelker J, Gomez E, McColm J.
    Br J Clin Pharmacol; 2016 May 13; 81(5):908-17. PubMed ID: 26648084
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, Viola DO, Furie RA, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer AE, Ji BN, Okily M, Roth DA, Quasny H, Ruperto N.
    RMD Open; 2021 Sep 13; 7(3):. PubMed ID: 34531304
    [Abstract] [Full Text] [Related]

  • 11. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
    Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, Roth DA, Zheng J, Tanaka Y.
    Ann Rheum Dis; 2018 Mar 13; 77(3):355-363. PubMed ID: 29295825
    [Abstract] [Full Text] [Related]

  • 12. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
    Schwarting A, Dooley MA, Roth DA, Edwards L, Thompson A, Wilson B.
    Lupus; 2016 Dec 13; 25(14):1587-1596. PubMed ID: 27488472
    [Abstract] [Full Text] [Related]

  • 13. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
    Genovese MC, Fleischmann RM, Greenwald M, Satterwhite J, Veenhuizen M, Xie L, Berclaz PY, Myers S, Benichou O.
    Ann Rheum Dis; 2013 Sep 01; 72(9):1461-8. PubMed ID: 23268367
    [Abstract] [Full Text] [Related]

  • 14. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, Illei GG, Drappa J, Wang L, Yoo S, CD1013 Study Investigators.
    Arthritis Rheumatol; 2017 Feb 01; 69(2):376-386. PubMed ID: 28130918
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.
    Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Struemper H, Roth D.
    Mod Rheumatol; 2019 May 01; 29(3):452-460. PubMed ID: 29792370
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study.
    Schiff M, Combe B, Dörner T, Kremer JM, Huizinga TW, Veenhuizen M, Gill A, Komocsar W, Berclaz PY, Ortmann R, Lee C.
    RMD Open; 2015 May 01; 1(1):e000037. PubMed ID: 26535134
    [Abstract] [Full Text] [Related]

  • 17. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG, Fusco BE.
    Clin Ther; 2012 May 01; 34(5):1006-22. PubMed ID: 22464040
    [Abstract] [Full Text] [Related]

  • 18. Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab.
    Hoffman RW, Merrill JT, Alarcón-Riquelme MM, Petri M, Dow ER, Nantz E, Nisenbaum LK, Schroeder KM, Komocsar WJ, Perumal NB, Linnik MD, Airey DC, Liu Y, Rocha GV, Higgs RE.
    Arthritis Rheumatol; 2017 Mar 01; 69(3):643-654. PubMed ID: 27723281
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study.
    Smolen JS, Weinblatt ME, van der Heijde D, Rigby WF, van Vollenhoven R, Bingham CO, Veenhuizen M, Gill A, Zhao F, Komocsar WJ, Berclaz PY, Ortmann R, Lee C.
    Ann Rheum Dis; 2015 Aug 01; 74(8):1567-70. PubMed ID: 25873635
    [Abstract] [Full Text] [Related]

  • 20. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
    Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven RF, Bengtsson AA, Reich A, de Vries DE, van Hartingsveldt B, Robinson DW, Gordon R, Hsu B.
    Arthritis Rheum; 2013 Oct 01; 65(10):2661-71. PubMed ID: 23896980
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.